Canadian research supplyResearch use onlyResearch peptide catalogueDocumentation pathsCanadian research supplyResearch use onlyResearch peptide catalogueDocumentation paths
Account
Research Library

Study 01 / source index

GLP-3 RT / Retatrutide

A cited index of the published phase 2 study and its official registration record.

Source record

The published study

This entry indexes the 2023 New England Journal of Medicine publication titled Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. The paper identifies retatrutide as LY3437943. [1]

Publication2023 / N Engl J Med[1]
Study designPhase 2 / randomized / double-blind / placebo-controlled[1] [2]
Registry recordNCT04881760 / 338 enrolled / completed[2]

How to read this entry

The links below lead to the original publication, its DOI record, and the official trial registry. They are provided so researchers can review source materials directly rather than relying on a product-page summary.

References

Source citations

  1. Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. doi:10.1056/NEJMoa2301972 ↗
  2. ClinicalTrials.gov. A Study of LY3437943 in Participants Who Have Obesity or Are Overweight. NCT04881760. Study record ↗